Murine CIK cells show tumor specific cytolysis in CD107a based degranulation analysis  by Baker, J. et al.
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SEPARATION OF CD4 T CELL-MEDIATED GRAFT-VERSUS-HOST RE-
SPONSES FROM THE GRAFT-VERSUS-LEUKEMIA EFFECT
Lewandowski, A.M.; Friedman, T.M.; Korngold, R. Kimmel Cancer
Center/Thomas Jefferson University, Philadelphia, PA.
Graft-versus-host disease (GVHD) can result from transplanta-
tion of blood and bone marrow cells into major histocompatibility
complex (MHC)-matched recipient mice due to donor T cell
recognition of minor histocompatibility antigens (miHA). Graft-
versus-leukemia (GVL) responses can be directed to distinct or
over expressed leukemia-restricted antigens presented by MHC
class I or class II molecules. In addition, donor T cells which are
responsible for the induction of GVHD may also mount a GVL
effect directed to shared host miHA on tumor cells. We have
previously described CD4 T cell-mediated lethal GVHD in the
B6 anti-BALB.B miHA model and characterized the B6 anti-host
response over the course of disease development, in the absence of
leukemia challenge. Using a BALB.B-derived myeloid leukemia
cell line (MMBALB7), we subsequently investigated the GVL
activity in this GVHD model. We ﬁrst transferred B6 CD4 T
cells, presensitized to the BALB.B leukemia cell line, to bone
marrow-reconstituted syngeneic recipients and observed effective
GVL protection against the leukemia challenge. Then, in order to
better characterize this B6 CD4 T cell anti-leukemia response, T
cell receptor V CDR3-size spectratype analysis was performed.
B6 mice were stimulated with the MMBALB7 leukemia cell line
and the CD4 T cell response from the draining lymph nodes was
analyzed. The B6 anti-leukemia spectratype results were compared
to the previously reported B6 anti-BALB.B GVHD responses.
These results indicate anti-leukemia VTCR usage that was either
unique or overlapping in both the GVHD and GVL responses.
Speciﬁcally, V 1 and 5 families were uniquely involved in the
anti-leukemia response, whereas V 3, 8.2, 8.3, 11, 13, and 14
families were skewed in both the anti-leukemia and anti-BALB.B
GVHD responses. The presence of V families that are likely
recognizing leukemia-restricted antigens in the GVL response
suggests that it is possible to separate these responses from those
responsible for GVHD, allowing for optimum immunotherapeutic
potential.
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ANALYSIS OF GENE EXPRESSION PROFILE IN PATIENTS WITH ACUTE
GRAFT VERSUS HOST DISEASE FOLLOWING HAEMATOPOIETIC STEM
CELL TRANSPLANTATION
Tabellini, L.; Lin, M.-T.; Fan, W.; Pogosova-Agadjanyan, E.; Stephens,
B.; Zhao, L.P.; Radich, J.; Hansen, J.A. Fred Hutchinson Cancer
Research Center, Seattle, WA.
To better understand the cellular events that precede clinical
onset of GVHD we compared gene expression proﬁles in patients
3 weeks after transplantation from normal donor following my-
eloablative conditioning. Blood leucocytes were obtained at sched-
uled times prior to administration of steroids. RNA was biotin
labeled and hybridized on Affymetrix HG U133A chips. In a ﬁrst
set of experiments we compared global gene expression proﬁles
among 15 patients and 10 normal controls. A total of 1176 genes
were differentially expressed between patients and controls. The
expression proﬁles of these 1176 genes was further compared
between 8 patients who developed GVHD within the next 1 to 5
days and 7 patients who remained GVHD free for at least 90 days.
Nine genes were differentially expressed in these two groups
(NFD1): 3 were increased, 6 were decreased in GVHD patients.
In addition to the global comparison, we examined expression for
a candidate list of 189 genes and found 6 genes (NFD1) associ-
ated with onset of GVHD: 4 were increased, 2 were decreased. In
a second set of experiments we compared changes occurring within
7 patients between 3 and 4 weeks post-transplant. Using a pairwise
comparison we found 55 increased genes and 88 decreased among
4 patients developing GVHD within 7 days. Among the increased
genes 3 were associated with adaptive immune response and 5 with
inﬂammation. Among the decreased genes 3 were associated with
cell metabolism, 6 with DNA repair, replication and cell cycle, 5
with signal transduction, 10 with adaptive immune response in-
cluding 4 T cell associated genes. These results demonstrate ex-
tensive changes in gene expression during early post-transplant
period the majority of which are not obviously associated with
immune response. By candidate gene approach we detected a
smaller number of genes associated with onset of GVHD. We
found that the most informative approach was to compare longi-
tudinal changes within the same patient. We observed a paradox-
ical decrease in the expression of genes associated with cell cycle
and T cell function. This may be explained by previous studies
demonstrating activation induced cell death during clinical
GVHD, and the ﬁnding of profound lymphopenia in patients with
GVHD. Further studies will be necessary to determine if gene
expression proﬁling can be useful in identifying a molecular “sig-
nature” for GVHD, and if this approach can be of value in mon-
itoring or predicting response to GVHD treatment.
147
DENLEUKIN DIFTITOX (ONTAK) FOR THE TREATMENT OF ADVANCED
STEROID REFRACTORY GRAFT-VERSUS-HOST DISEASE (SR-GVHD): A
SINGLE INSTITUTION EXPERIENCE
Bubalo, J.S.; Maziarz, R.T.; Subbiah, N.; Curtin, P.T.; Simic, A.;
Hayes-Lattin, B.M.; Schubach, S.E.; Jacoby, C.E.; Leis, J.F. Oregon
Health & Science University, Portland, OR
SR-GVHD is a leading cause of morbidity and mortality follow-
ing allogeneic stem cell transplantation. Denileukin diftitox (DD),
a recombinant fusion protein composed of the cytocidal A chain of
diphtheria toxin and binding portion of interleukin-2, has potent
activity against activated CD25T cells important in the etiology
of GVHD. Recent reports suggest that DD may have therapeutic
activity for the treatment of SR-GVHD. SR-GVHD was deﬁned
as lack of response or disease progression after at least 7 days of
treatment with methylprednisolone at 2 mg/kg. Eleven patients
received allogeneic transplant, 2 after MRD and 9 after URD (7
matched, 1 C antigen mismatch, 1 three allele mismatch). GVHD
prophylaxis consisted of cyclosporine (CsA), methotrexate (MTX),
plus steroids (10) or CsA and MTX (1). Seven patients developed
acute SR-GVHD overall grade III (2) or IV (5) while 4 had chronic
extensive SR-GVHD. Five patients had 2 organ (skin and GI)
grade IV GVHD and 6 had 3 organ involvement (skin, GI, and
liver). Six patients had prior admissions for treatment of GVHD
and all patients had failed a median of 2.5 agents (range 1–5) prior
to DD including dacluzimab (4), MMF (6), tacrolimus (7), siroli-
mus (1) and beclomethasone (1). Median day to DD therapy after
stem cell transplant was day 76 (30–311). Planned treatment for
DD was at a dose of 600 mcg (approximately 9 mcg/kg) on days 1,
3, 5, 15, 17 and 19 (Ho, Blood, 2004). Two patients with cGVHD
developed hyperbilirubinemia without elevation of hepatic en-
zymes on DD. Five patients including 3 of 4 with cGVHD died
prior to completing the full course of treatment (1–3 doses). These
patients succumbed to GI bleed secondary to gut GVHD and
CMV colitis (1), fungal pneumonia (2), and ARDS (2). Six patients
received all six doses of DD. All 6 showed response to treatment
with 1 patient with grade III aGVHD achieving a CR and 5
achieving a PR, deﬁned as at least a one overall grade improvement
in GVHD staging. Five of the 6 patients have died with patients
dying of CMV pneumonia (1), multi-organ failure (1), IPS (1),
aspergillus pneumonia (1), and respiratory arrest (1). Steroids could
be tapered in 8 of 10 patients. Median survival for the entire group
was 20 days from the onset of DD treatment (range 5–440 days)
with median survival of 34 days for patients who received all 6
doses of DD. These results demonstrate that patients with ad-
vanced SR-GVHD can respond to DD and suggest that earlier
treatment may improve outcomes.
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MURINE CIK CELLS SHOW TUMOR SPECIFIC CYTOLYSIS IN CD107A
BASED DEGRANULATION ANALYSIS
Baker, J.; Schulz, S.; Beilhack, A.; Eftekhari, K.; Negrin, R.S. Depart-
ment of Medicine, Division of BMT, Stanford University, Stanford, CA.
Immunotherapy with cytokine induced killers cells (CIK) is ef-
fective in the treatment of malignancies in several murine models.
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Previous studies on human T lymphocytes have shown that the
degranulation marker CD107a can be used to deﬁne T cells, which
show tumor speciﬁc cytolysis. To determine whether CD107a can
be used in the murine setting as a marker for cytolysis, we ﬁrst
tested the degranulation activity on splenocytes from C57BL/6
(H-2b), FVB (H-2q) or Balb/c (H-2d) against Balb/c splenocytes.
Results from the mixed lymphocyte cytolytic assays (MLCA) and
cytolytic assays [51Cr] showed a high degree of correlation with
CD107a expression by FACS analyses. We next analyzed the
degranulation activity of murine CIK cells by evaluating their
capacity to mobilize CD107a to the cell membrane as a parameter
of tumor speciﬁc cytolysis. CIK cells showed a high cytolytic
capacity in 51Cr assays when directed against syngeneic and allo-
geneic tumor cell lines (A20, P3X63, EL4, Yac-1 and P815). CIK
cytotoxicity correlated with CD107a expression by FACS analyses.
Immunoﬂuorescence microscopy could conﬁrm the existence of
CD107a positive cytolytic granules in CIK cells from tumor cyto-
toxic assays. Using in vivo Bioluminescence Imaging (BLI) we
characterized the migration pattern of CIK cells derived from a
luciferase expressing transgenic mouse in tumor-bearing mice as
compared to healthy controls. Furthermore, Balb/c mice bearing a
sub-cutaneous A20 lymphoma, revealed tumor-speciﬁc homing of
CIK cells and reduction of the tumor size within 3 days after i.v.
injection. To identify tumor-speciﬁc CIK in vivo we are currently
combining imaging techniques with CD107a degranulation anal-
ysis. These data will help to elucidate the complex cellular inter-
action mounting a graft-versus-tumor response, which depends on
an effective combination of efﬁcient trafﬁcking, recognition and
elimination of the tumor cells.
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METHOTREXATE ALTERS HEMATOPOIETIC RECOVERY AND ENGRAFT-
MENT KINETICS WHEN ADDED TO CYCLOSPORINE FOR ACUTE GVHD
PROPHYLAXIS AFTER REDUCED-INTENSITY STEM CELL TRANSPLAN-
TATION
Dean, R.M.; Fowler, D.H.; Odom, J.; Castro, K.M.; Kasten-Sportes, C.;
Wilson, W.H.; Gress, R.E.; Bishop, M.R. Center for Cancer Research,
National Cancer Institute, Bethesda, MD.
Methotrexate (MTX) is a standard drug for graft-versus-host
disease (GVHD) prophylaxis, but its effects on hematopoietic re-
covery and donor engraftment in the setting of reduced-intensity
stem cell transplantation (RIST) are not well described. We com-
pared these parameters and acute GVHD in patients with hema-
tologic malignancies undergoing RIST on 2 consecutive clinical
trials using identical reduced-intensity conditioning (ﬂudarabine
and cyclophosphamide). Group 1 included 50 patients receiving
cyclosporine (CSA) alone for GVHD prophylaxis after RIST.
Group 2 included 24 patients receiving CSA MTX (5 mg/m2 on
days 1, 3, 6, 11) for GVHD prophylaxis. The groups were
similar with respect to host immune status before RIST, age, and
allograft dose of CD34 and CD3 cells. All patients in each group
received salvage therapy with etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin plus ﬂudarabine (EPOCH-F)
prior to RIST. Fourteen patients in the CSA/MTX group also
received rituximab with EPOCH-F. Hematopoietic recovery was
delayed in the CSA/MTX group, with median neutrophil recovery
(500/L) and platelet recovery (100K/L) occurring 3 and 6.5
days later, respectively, than in the CSA group. Donor engraftment
was rapid and complete for most patients in each group (median
total mononuclear cell chimerism 100% at day 28 for both
groups), and no patient experienced graft rejection. However, full
donor chimerism (95%) was less common for CSA/MTX (75%
at day28, 71% at day100) than for CSA (90% at day28, 97%
at day 100). Adding MTX to CSA decreased the incidence and
severity of acute GVHD. Grade 2–4 acute GVHD occurred in
33/50 (66%) CSA patients, versus 9/24 (38%) CSA/MTX patients.
Grade 3–4 GVHD affected 17/50 (34%) CSA patients, including
6 with grade 4 GVHD and 8 with steroid-refractory disease. In
contrast, only 5/24 (21%) of CSA/MTX patients had grade 3
GVHD, while none had grade 4 or steroid-refractory GVHD. No
treatment-related deaths occurred in the CSA/MTX group, but 14
CSA patients died of treatment-related complications. Thus, the
addition of MTX to CSA markedly attenuates the GVH response
post RIST, slowing donor engraftment and delaying hematopoietic
recovery. These data illustrate the sensitivity of engraftment kinet-
ics to the intensity of GVHD prophylaxis following RIST. Further
studies should determine if CSA/MTX will be associated with an
increased risk of disease progression after RIST.
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GRADE 2–4 ACUTE GRAFT-VERSUS-HOST DISEASE AND EXTENSIVE
CHRONIC GRAFT VERSUS HOST DISEASE ARE ASSOCIATED WITH SIG-
NIFICANTLY DECREASED SURVIVAL FOLLOWING REDUCED INTENSITY
ALLOGENEIC STEM CELL TRANSPLANTATION
Chan, G.W.1; Klein, A.K.1; Sprague, K.A.1; Miller, K.B.2; Foss, F.M.1
1. Tufts-New England Medical Center, Boston, MA; 2. Beth Israel
Deaconess Medical Center, Boston, MA.
Grade 2–4 acute graft-versus-host-disease (aGVHD) and extensive
chronic GVHD (cGVHD) are associated with decreased overall sur-
vival (OS) following conventional allogeneic stem cell transplantation
but their impact on reduced intensity transplantation remains contro-
versial. We evaluated the impact of GVHD on survival in 112 high-
risk patients, median age 50 years (range 18–70), with AML (n29),
MDS (n19), CML (n9), CLL (n5), ALL (n3), HD (n10),
NHL (n16), MM (n9), MMM (n7), PNH (n2), or renal cell
carcinoma (n3), who underwent a reduced intensity preparative
regimen of extracorporeal photopheresis day 7, 6, pentostatin 8
mg/m2 by continuous intravenous infusion day 5 through 4, and
total body irradiation in three 200 cGy fractions day3,2, followed
by allogeneic bone marrow stem cell infusion from 6/6 HLAmatched
related (n70), 5/6 HLA matched related (n10), or matched unre-
lated (n32) donors. Thirty patients had prior autologous stem cell
transplantation and 5 patients had prior conventional allogeneic stem
cell transplantation. Full donor chimerism occurred in 89% of pa-
tients. Day 100 transplant related mortality (TRM) was 20%. The
disease relapse rate was 22%. Grade 2, 3 or 4 aGVHD occurred in
7%, 6%, and 6% of patients respectively. The one-year OS by
aGVHD grade was 70% for grade 0, 69% for grade 1, 29% for grade
2, 17% for grade 3, and 0% for grade 4. Grade 2–4 aGVHD was
associated with higher day 100 TRM (37% vs 14%: p0.03) and
decreased median OS (5 months vs “not reached”: p0.001). Median
OS was lower among patients with grade 2–4 aGVHD as compared
to patients with grade 0–1 aGVHD in matched related donor trans-
plants (5 months vs “not reached”: p0.002) and in mismatched
related or matched unrelated donor transplants (6 months vs 35
months: p0.0004). Patients with grade 2 or grade 3–4 aGVHD had
similar median OS (6 months vs 3 months: p0.24). Patients with
limited or no cGVHD had similar one-year OS (90% vs 79%) but
patients with extensive cGVHD had a signiﬁcantly worse one-year
OS (56% vs 82% p0.0007). In conclusion, high-risk patients who
undergo reduced intensity transplantation and develop grade 2–4
aGVHD or extensive cGVHD tolerate GVHD poorly, leading to
signiﬁcantly higher TRM and decreased overall survival. Patients with
grade 2 aGVHD or grade 3–4 aGVHD have similarly poor OS. To
improve survival, reduced intensity transplantation regimens that de-
crease the incidence of grade 2–4 aGVHDor extensive cGVHDneed
to be developed.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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SIGNIFICANCE OF ONE HUMAN LEUKOCYTE ANTIGEN MISMATCH ON
OUTCOME OF NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANS-
PLANTATION FROM RELATED DONORS USING THE MEXICAN SCHED-
ULE
Ruiz-Arguelles, G.J.1,2; Lopez-Martinez, B.2; Manzano, C.1; Gomez-
Rangel, J.D.1; Lobato-Mendizabal, E.1 1. Centro de Hematologia y
Medicina Interna, Puebla, Mexico; 2. Laboratorios Clinicos de Puebla,
Puebla, Mexico.
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